Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

Core Insights - Praxis Precision Medicines is set to present new preclinical and clinical data on its precision epilepsy pipeline at the American Epilepsy Society Annual Meeting from December 5-9, 2025, in Atlanta, Georgia [1][2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly those related to neuronal excitation-inhibition imbalance [13] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [13] Pipeline and Research Highlights - The company will showcase its precision epilepsy programs through multiple presentations, including late-breaking presentations and a dedicated scientific exhibit at Booth 217 [3][4] - Key programs being highlighted include vormatrigine, relutrigine, and elsunersen, with specific presentations scheduled for December 6 and 8 [4][5][6] - Vormatrigine is a next-generation treatment for focal onset seizures and generalized epilepsy, showing superior selectivity and potency in preclinical studies [10] - Relutrigine is in development for developmental and epileptic encephalopathies, demonstrating robust seizure control in preclinical models and well-tolerated results in Phase 1 studies [11] - Elsunersen targets SCN2A gene expression to treat early-onset seizures, showing significant reductions in seizures and improved outcomes in preclinical models [12] Event Participation - Praxis will engage with attendees at the AES meeting, inviting them to learn more about the company's research and commitment to advancing epilepsy therapies [3][4] - The scientific exhibit will feature all conference posters, with team members available for discussions on clinical updates and progress [4]